| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers C > Headlines for ChondroGene Ltd. > News item |
ChondroGene's ProstateSentry detects aggressive forms of prostate cancer
By Lisa Kerner
Erie, Pa., March 22 - ChondroGene Ltd. said its ProstateSentry blood-based prostate cancer detection test done with a simple blood sample, in combination with measured prostate-specific antigen (PSA) levels, differentiates aggressive forms of prostate cancer.
The test was developed using ChondroGene's proprietary Sentinel Principle technology, capable of identifying blood biomarkers for disease or medical condition, according to a company news release.
ChondroGene said it has collected more than 500 blood samples in North America and Asia from patients with elevated PSA levels, who have also undergone prostate biopsy and Gleason scoring (measure of prostate tumor aggressiveness).
These samples were used to identify blood-based biomarker sets, forming the basis of molecular diagnostic tests for the detection of aggressive forms of prostate cancer.
In one study of a four-gene biomarker set, in combination with PSA levels, the test was able to discriminate patients with prostate cancer having Gleason scores greater than seven (10 being the highest score) from controls with sensitivities greater than 90%.
Prostate cancer is the third leading cause of cancer death after lung and colon cancer. Current methods of screening include measurement of PSA blood levels and the digital rectal exam followed by prostate biopsies if screening results are positive.
"This is our second cancer test development effort after our lead product, ColonSentry, for the detection of colon cancer and pre-cancerous polyps. ChondroGene's proprietary biomarker discovery process is a powerful tool for identifying and validating biomarkers from a simple blood sample," president and chief executive officer Dr. K. Wayne Marshall said in the release.
Toronto, Ont.-based ChondroGene is applying the Sentinel Principle to cancer, arthritis, cardiovascular disease and neurological disorders.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.